I'll pull the relevant safety profile, precedent criteria, and lab thresholds to ground this in evidence.
{
"drug_class": "DLL3 T-cell engager",
"class_effect_aes": [
"Cytokine release syndrome (CRS) \u2014 common, mostly cycle-1, can be high-grade",
"Immune effector cell-associated neurotoxicity syndrome (ICANS) / neurotoxicity",
"Cytopenias (neutropenia, anemia, thrombocytopenia)",
"Hypogammaglobulinemia / infection risk from on-target B/neuroendocrine effects",
"Tumor flare / pyrexia"
],
"monitoring": [
"Inpatient monitoring for CRS during step-up/priming doses (cycle 1)",
"Frequent vitals, ferritin/CRP trend during CRS window",
"Baseline + on-treatment neuro exam (ICE score) for ICANS",
"Baseline ECG/echo if cardiac reserve is a concern during CRS",
"CBC with differential before each dose"
],
"contraindicated_comorbidities": [
"Active CNS metastases / leptomeningeal disease (raises ICANS danger)",
"Active autoimmune CNS disease or seizure disorder",
"Inadequate cardiac reserve (CRS hemodynamic stress) \u2014 recent MI, NYHA III/IV CHF",
"Active uncontrolled infection (CRS masks/worsens sepsis)",
"Significant baseline hypoxia / poor pulmonary reserve"
],
"ddi_flags": [
"Live vaccines contraindicated (immune activation)",
"Chronic systemic immunosuppression / high-dose steroids blunt efficacy and confound CRS grading",
"Tocilizumab/steroids must be available on-site as CRS rescue"
],
"notes": "First-in-human TCEs need a step-up/priming dose schedule and mandated CRS/ICANS rescue medication on hand; cycle-1 inpatient observation is standard."
}{
"indication": "ES-SCLC",
"precedent_trials": [
"Tarlatamab DeLLphi-301/304 (DLL3 TCE)",
"IMpower133 (1L chemo-IO)"
],
"inclusion": [
"Histologically/cytologically confirmed extensive-stage SCLC",
"Relapsed/refractory after >=1 prior platinum-based regimen (line per protocol)",
"Measurable disease per RECIST v1.1",
"ECOG performance status 0-1",
"Adequate hematologic, hepatic, renal organ function (see lab thresholds)",
"Life expectancy >=12 weeks"
],
"exclusion": [
"Untreated/active/symptomatic CNS metastases (treated, stable may be allowed)",
"Leptomeningeal disease / carcinomatous meningitis",
"Active autoimmune disease or condition needing systemic immunosuppression (for IO/TCE)",
"Insufficient washout from prior anticancer therapy (e.g. ~3-4 wks or 5 half-lives)",
"Uncontrolled intercurrent illness / active infection",
"Second malignancy requiring active treatment"
],
"notes": "DLL3 TCE precedents often allow treated/stable brain mets but exclude active CNS disease specifically because of ICANS/neurotoxicity risk."
}{
"hematologic": [
{
"parameter": "Absolute neutrophil count (ANC)",
"typical_threshold": ">= 1.5 x 10^9/L",
"rationale": "Adequate marrow reserve before a myelosuppressive agent; lower (>=1.0) sometimes allowed if marrow involvement."
},
{
"parameter": "Platelets",
"typical_threshold": ">= 100 x 10^9/L (>=75 if marrow involvement)",
"rationale": "Bleeding risk and tolerance of thrombocytopenia."
},
{
"parameter": "Hemoglobin",
"typical_threshold": ">= 9.0 g/dL (transfusion-independent)",
"rationale": "Baseline reserve; many protocols require independence from recent transfusion."
}
],
"hepatic": [
{
"parameter": "Total bilirubin",
"typical_threshold": "<= 1.5 x ULN (<=3 x ULN if Gilbert's/liver mets)",
"rationale": "Hepatic clearance reserve; relaxed for documented Gilbert's or hepatic metastases."
},
{
"parameter": "AST / ALT",
"typical_threshold": "<= 3 x ULN (<=5 x ULN if liver metastases)",
"rationale": "Baseline hepatocellular integrity; key for hepatotoxic agents (PI3Ki, JAKi)."
},
{
"parameter": "Albumin",
"typical_threshold": ">= 2.8-3.0 g/dL (some protocols)",
"rationale": "Synthetic liver function / nutritional status, esp. GI cancers."
}
],
"renal": [
{
"parameter": "Creatinine clearance (Cockcroft-Gault)",
"typical_threshold": ">= 50-60 mL/min",
"rationale": "Renal elimination reserve; threshold depends on renal clearance of the drug."
},
{
"parameter": "Serum creatinine",
"typical_threshold": "<= 1.5 x ULN",
"rationale": "Simpler surrogate when CrCl not used."
}
],
"cardiac": [
{
"parameter": "Left-ventricular ejection fraction (LVEF)",
"typical_threshold": ">= 50% (institutional LLN)",
"rationale": "Required for cardiotoxic agents (anti-HER2, anthracycline exposure)."
},
{
"parameter": "QTc (Fridericia)",
"typical_threshold": "<= 470 ms (women) / <= 450 ms (men)",
"rationale": "Exclude baseline prolongation for QT-liable agents; pair with congenital long-QT exclusion."
}
],
"coagulation_metabolic": [
{
"parameter": "INR / aPTT (if on anticoagulation off-study)",
"typical_threshold": "within therapeutic range / <= 1.5 x ULN",
"rationale": "Bleeding risk, esp. for agents with hemorrhage signal (BTKi)."
},
{
"parameter": "Fasting glucose / HbA1c",
"typical_threshold": "HbA1c <= 6.5-8.0% per protocol",
"rationale": "Baseline glycemic control for hyperglycemia-liable agents (PI3K-alpha)."
}
],
"notes": "Teaching-snapshot typical oncology cutoffs. Exact thresholds and relaxations (marrow involvement, liver mets, Gilbert's) are drug- and protocol-specific and must be set against the investigator's brochure and standard of care."
}Authored for a dose-escalation FIH study with mandatory step-up/priming dosing and cycle-1 inpatient CRS/ICANS observation. Design intent flagged where criteria deliberately trade enrollability against the CRS/neurotoxicity profile of the class.
Disease
1. Histologically or cytologically confirmed extensive-stage small cell lung cancer (ES-SCLC).
2. Relapsed or refractory disease after ≥1 prior line of platinum-based chemotherapy. (Note: a prior anti-PD-(L)1, e.g., per IMpower133, is expected in most patients and is permitted; for FIH, do not over-restrict prior lines — keeping ≥1 rather than mandating a specific number preserves enrollability in a heavily pretreated population.)
3. At least one measurable lesion per RECIST v1.1.
4. (Optional biomarker enrichment) Archival or fresh tumor available for DLL3 expression assessment. For a FIH escalation, recommend collecting DLL3 status for correlative analysis but not gating enrollment on it until a threshold is defined — gating prematurely shrinks the pool without validated cutoff.
Performance & reserve
5. ECOG performance status 0–1.
6. Life expectancy ≥12 weeks.
Organ function (within ~7 days of first dose; no growth-factor/transfusion support within 14 days for hematologic values)
7. ANC ≥ 1.5 × 10⁹/L.
8. Platelets ≥ 100 × 10⁹/L.
9. Hemoglobin ≥ 9.0 g/dL, transfusion-independent.
10. Total bilirubin ≤ 1.5 × ULN (≤ 3 × ULN if documented Gilbert's or hepatic metastases).
11. AST/ALT ≤ 3 × ULN (≤ 5 × ULN if hepatic metastases).
12. Creatinine clearance ≥ 50 mL/min (Cockcroft-Gault).
Class-specific safety baselines (CRS/ICANS-driven)
13. Adequate cardiac reserve to tolerate CRS hemodynamic stress: LVEF ≥ 50% by ECHO/MUGA and no clinically significant cardiac disease (see exclusions).
14. Adequate pulmonary reserve: baseline O₂ saturation ≥ 92% on room air. (CRS can precipitate hypoxia; poor baseline pulmonary function compounds danger — relevant given SCLC's smoking-related comorbidity burden.)
15. Baseline normal neurologic exam with documented ICE (Immune effector Cell-associated Encephalopathy) score — establishes the reference point for ICANS grading.
General
16. Adequate washout from prior anticancer therapy: ≥3 weeks or 5 half-lives (whichever shorter) before first dose; recovery of prior toxicities to ≤ Grade 1 (excluding alopecia, stable neuropathy).
17. Age ≥18, able to comply with inpatient cycle-1 monitoring, and provide written informed consent.
CNS — central to ICANS risk mitigation
1. Active, untreated, or symptomatic CNS metastases. Treated and stable brain metastases are permitted if: completed local therapy ≥2–4 weeks prior, off therapeutic-dose corticosteroids (≤10 mg/day prednisone-equivalent), and radiographically stable. (This precedent-based allowance — used in DLL3 TCE programs — is the single biggest enrollability lever, since untreated CNS disease is common in SCLC; only active CNS disease is excluded because of ICANS overlap.)
2. Leptomeningeal disease / carcinomatous meningitis.
3. History of seizure disorder, or active autoimmune/inflammatory CNS disease — confounds and amplifies ICANS.
Cardiac/pulmonary — CRS tolerability
4. Recent myocardial infarction (≤6 months), unstable angina, NYHA Class III/IV heart failure, or other clinically significant uncontrolled cardiac disease.
5. Clinically significant baseline hypoxia or poor pulmonary reserve beyond inclusion #14 threshold.
6. QTc(F) > 470 ms (women) / > 450 ms (men), or congenital long-QT syndrome.
Immune/infectious — CRS confounding & on-target risk
7. Active autoimmune disease or condition requiring chronic systemic immunosuppression / high-dose corticosteroids. (Steroids blunt TCE efficacy and confound CRS grading.)
8. Active uncontrolled infection — CRS can mask or worsen sepsis; pyrexia overlaps with CRS presentation.
9. Known HIV with uncontrolled disease, or active HBV/HCV (controlled/treated viral disease may be permitted per protocol).
10. Live vaccine within 4 weeks of first dose.
11. Pre-existing hypogammaglobulinemia of clinical significance / history of recurrent serious infection (given on-target hypogammaglobulinemia and infection signal — consider monitoring rather than hard exclusion to protect enrollability).
General
12. Insufficient washout (see inclusion #16) or unresolved prior-therapy toxicity > Grade 1.
13. Second malignancy requiring active systemic treatment.
14. Pregnancy/lactation; refusal of effective contraception.
15. Any condition that, in the investigator's judgment, precludes safe completion of mandated cycle-1 inpatient monitoring.
| Lever | Decision | Rationale |
|---|---|---|
| Brain mets | Exclude only active; allow treated/stable | Largest enrollability gain; ICANS risk concentrated in active CNS disease |
| Prior lines | ≥1 platinum line, no upper cap | Heavily pretreated SCLC population; over-restricting starves the trial |
| DLL3 expression | Collect, don't gate (FIH) | No validated cutoff yet; gate later if escalation data warrant |
| Cardiac/pulmonary | LVEF ≥50%, SpO₂ ≥92% | Floor for CRS hemodynamic/hypoxic stress without excluding typical SCLC comorbidity |
| Hypogammaglobulinemia | Monitor preferentially over exclude | Manageable with Ig replacement; hard exclusion would over-cull |
Protocol-level safeguards (not eligibility, but required by the class): step-up/priming dose schedule; cycle-1 inpatient observation through the CRS window; tocilizumab and corticosteroids on-site as mandated rescue; serial ferritin/CRP/vitals trending; baseline + scheduled ICE-score neuro assessments.
⚠️ These are precedent-grounded teaching-level criteria. Exact thresholds, washout windows, viral-disease handling, and any DLL3 cutoff must be finalized against the Investigator's Brochure, the specific molecule's PK/half-life, and regulatory/IRB input.
Want me to draft the corresponding CRS/ICANS grading-and-management appendix or the dose-limiting toxicity (DLT) definitions for the escalation cohorts next?
Authored for a dose-escalation FIH study with mandatory step-up/priming dosing and cycle-1 inpatient CRS/ICANS observation. Design intent flagged where criteria deliberately trade enrollability against the CRS/neurotoxicity profile of the class.
Disease
1. Histologically or cytologically confirmed extensive-stage small cell lung cancer (ES-SCLC).
2. Relapsed or refractory disease after ≥1 prior line of platinum-based chemotherapy. (Note: a prior anti-PD-(L)1, e.g., per IMpower133, is expected in most patients and is permitted; for FIH, do not over-restrict prior lines — keeping ≥1 rather than mandating a specific number preserves enrollability in a heavily pretreated population.)
3. At least one measurable lesion per RECIST v1.1.
4. (Optional biomarker enrichment) Archival or fresh tumor available for DLL3 expression assessment. For a FIH escalation, recommend collecting DLL3 status for correlative analysis but not gating enrollment on it until a threshold is defined — gating prematurely shrinks the pool without validated cutoff.
Performance & reserve
5. ECOG performance status 0–1.
6. Life expectancy ≥12 weeks.
Organ function (within ~7 days of first dose; no growth-factor/transfusion support within 14 days for hematologic values)
7. ANC ≥ 1.5 × 10⁹/L.
8. Platelets ≥ 100 × 10⁹/L.
9. Hemoglobin ≥ 9.0 g/dL, transfusion-independent.
10. Total bilirubin ≤ 1.5 × ULN (≤ 3 × ULN if documented Gilbert's or hepatic metastases).
11. AST/ALT ≤ 3 × ULN (≤ 5 × ULN if hepatic metastases).
12. Creatinine clearance ≥ 50 mL/min (Cockcroft-Gault).
Class-specific safety baselines (CRS/ICANS-driven)
13. Adequate cardiac reserve to tolerate CRS hemodynamic stress: LVEF ≥ 50% by ECHO/MUGA and no clinically significant cardiac disease (see exclusions).
14. Adequate pulmonary reserve: baseline O₂ saturation ≥ 92% on room air. (CRS can precipitate hypoxia; poor baseline pulmonary function compounds danger — relevant given SCLC's smoking-related comorbidity burden.)
15. Baseline normal neurologic exam with documented ICE (Immune effector Cell-associated Encephalopathy) score — establishes the reference point for ICANS grading.
General
16. Adequate washout from prior anticancer therapy: ≥3 weeks or 5 half-lives (whichever shorter) before first dose; recovery of prior toxicities to ≤ Grade 1 (excluding alopecia, stable neuropathy).
17. Age ≥18, able to comply with inpatient cycle-1 monitoring, and provide written informed consent.
CNS — central to ICANS risk mitigation
1. Active, untreated, or symptomatic CNS metastases. Treated and stable brain metastases are permitted if: completed local therapy ≥2–4 weeks prior, off therapeutic-dose corticosteroids (≤10 mg/day prednisone-equivalent), and radiographically stable. (This precedent-based allowance — used in DLL3 TCE programs — is the single biggest enrollability lever, since untreated CNS disease is common in SCLC; only active CNS disease is excluded because of ICANS overlap.)
2. Leptomeningeal disease / carcinomatous meningitis.
3. History of seizure disorder, or active autoimmune/inflammatory CNS disease — confounds and amplifies ICANS.
Cardiac/pulmonary — CRS tolerability
4. Recent myocardial infarction (≤6 months), unstable angina, NYHA Class III/IV heart failure, or other clinically significant uncontrolled cardiac disease.
5. Clinically significant baseline hypoxia or poor pulmonary reserve beyond inclusion #14 threshold.
6. QTc(F) > 470 ms (women) / > 450 ms (men), or congenital long-QT syndrome.
Immune/infectious — CRS confounding & on-target risk
7. Active autoimmune disease or condition requiring chronic systemic immunosuppression / high-dose corticosteroids. (Steroids blunt TCE efficacy and confound CRS grading.)
8. Active uncontrolled infection — CRS can mask or worsen sepsis; pyrexia overlaps with CRS presentation.
9. Known HIV with uncontrolled disease, or active HBV/HCV (controlled/treated viral disease may be permitted per protocol).
10. Live vaccine within 4 weeks of first dose.
11. Pre-existing hypogammaglobulinemia of clinical significance / history of recurrent serious infection (given on-target hypogammaglobulinemia and infection signal — consider monitoring rather than hard exclusion to protect enrollability).
General
12. Insufficient washout (see inclusion #16) or unresolved prior-therapy toxicity > Grade 1.
13. Second malignancy requiring active systemic treatment.
14. Pregnancy/lactation; refusal of effective contraception.
15. Any condition that, in the investigator's judgment, precludes safe completion of mandated cycle-1 inpatient monitoring.
| Lever | Decision | Rationale |
|---|---|---|
| Brain mets | Exclude only active; allow treated/stable | Largest enrollability gain; ICANS risk concentrated in active CNS disease |
| Prior lines | ≥1 platinum line, no upper cap | Heavily pretreated SCLC population; over-restricting starves the trial |
| DLL3 expression | Collect, don't gate (FIH) | No validated cutoff yet; gate later if escalation data warrant |
| Cardiac/pulmonary | LVEF ≥50%, SpO₂ ≥92% | Floor for CRS hemodynamic/hypoxic stress without excluding typical SCLC comorbidity |
| Hypogammaglobulinemia | Monitor preferentially over exclude | Manageable with Ig replacement; hard exclusion would over-cull |
Protocol-level safeguards (not eligibility, but required by the class): step-up/priming dose schedule; cycle-1 inpatient observation through the CRS window; tocilizumab and corticosteroids on-site as mandated rescue; serial ferritin/CRP/vitals trending; baseline + scheduled ICE-score neuro assessments.
⚠️ These are precedent-grounded teaching-level criteria. Exact thresholds, washout windows, viral-disease handling, and any DLL3 cutoff must be finalized against the Investigator's Brochure, the specific molecule's PK/half-life, and regulatory/IRB input.
Want me to draft the corresponding CRS/ICANS grading-and-management appendix or the dose-limiting toxicity (DLT) definitions for the escalation cohorts next?
Expected-coverage checklist for drug class 'DLL3 T-cell engager' — a grading aid, NOT ground truth. A strong I/E list visibly protects against each liability (exclusion / lab cutoff / monitoring) while keeping the target population enrollable.
| Class-effect liability to address | Why it constrains eligibility |
|---|---|
| Cytokine release syndrome (CRS) — common, mostly cycle-1, can be high-grade | Drives cycle-1 inpatient monitoring + exclude poor cardiac/pulmonary reserve and active infection. |
| Immune effector cell-associated neurotoxicity syndrome (ICANS) / neurotoxicity | Exclude active CNS mets / leptomeningeal / seizure disorder; baseline neuro exam. |
| Cytopenias (neutropenia, anemia, thrombocytopenia) | Set ANC/platelet/hemoglobin thresholds; CBC monitoring. |
| Hypogammaglobulinemia / infection risk from on-target B/neuroendocrine effects | Baseline TB/HBV/HCV screening; exclude active/latent untreated infection. |
| Tumor flare / pyrexia | Should be reflected in an exclusion, lab threshold, or monitoring requirement. |